Shares of Arcutis Biotherapeutics, Inc. (ARQT) have gained 2.4% over the past four weeks to close the last trading session at 9.34,buttherecouldstillbeasolidupsideleftinthestockifshort−termpricetargetsofWallStreetanalystsareanyindication.Goingbythepricetargets,themeanestimateof18.67 indicates a potential upside of 99.9%.The mean estimate comprises six short-term price targets with a standard deviation of 4.80.Whilethelowestestimateof11 indicates a 17.8% increase fr ...